The Singapore Heart Lesion Analyser, called Sense, will be tested at three hospitals in Singapore starting Q3 2025 for heart scan analysis.
The one-year trial will involve 300 patients and aims to reduce coronary artery disease assessment time from hours to under 10 minutes.
Sense supports, rather than replaces, doctors’ clinical decisions, requiring their review and confirmation of the AI’s findings.
The system has demonstrated 85% to 99% accuracy in earlier tests and could significantly impact early diagnosis of coronary artery disease, which caused 8,311 deaths in Singapore in 2023.
Developed by the CVS.AI lab at NHCS, Sense builds on previous AI work using a large dataset from CT scans to improve speed and accuracy in heart problem detection.